Headlines

Sanofi abandons phase 2 trial of Denali’s multiple sclerosis candidate

The big pharma company Sanofi has discontinued a phase 2 trial of U.S. partner Denali Therapeutics’ oditrasertib for the treatment of multiple sclerosis after the drug failed to perform.

Corden Phama - staying on top of manufacturing trends

How a CDMO is staying on top of API and drug product manufacturing trends

As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug developers and manufacturers must adapt their strategies to keep pace with the evolving landscape.

Paid for and content provided by METTLER TOLEDO

Achieving data integrity: Best practices for secure and reliable data management

In today's regulatory landscape, ensuring data integrity is crucial for compliance and process visibility. How can organizations enhance accuracy, consistency, and reliability?

AstraZeneca licenses CSPC’s cardiovascular drug in $2 billion deal

The big pharma company AstraZeneca has forged a licensing pact worth $2 billion with the Chinese firm CSPC Pharmaceutical Group for access to an experimental small molecule treatment for dyslipidemia.

Antag Therapeutics gets FDA clearance to start clinical trials with new obesity drug

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a first-in-class treatment for obesity.

Preparing for the US Biosecure Act - what does it mean for the pharma industry?

The US Biosecure Act was passed by the House of Representatives in September and seems likely to become law.

Small molecules in focus as Recipharm bolsters global production facilities

Months after divesting seven European sites, the Swedish contract development and manufacturing organisation (CDMO) Recipharm is expanding its manufacturing capacity with undisclosed investments in its small molecule offerings.

Innovent and Ask Pharm join forces to commercialize third-generation lung cancer therapy

The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.

SK pharmteco to strengthen small molecule and peptide capacity with $260 million investment

SK Group’s contract development and manufacturing organization (CDMO) arm SK pharmteco is spending $260 million to expand its small molecule and peptide manufacturing muscle in South Korea.

LoQus23 Therapeutics raises £35m to advance therapy for Huntington’s disease

The proceeds of the financing will support the development of LoQus23’s lead candidate, a small molecule inhibitor that is expected to enter the clinic in 2026.